I feel the 10k broke out Keventrin specifically from the other compounds for a particular reason. They may have negotiated the purchase of B and P and K was going to be left and essentially IPIX would be a holding company for the K asset. This may or may not have changed as negotiations furthered. My overall prospective has been that B would be partnered if P results were not up to par to the partnering company but if P results were good then a complete buyout would occur.

I think the purchasing company may take a controlling stake in order to direct all future decisions of each compound including K since the 10k breaks out Kevetrin and future compensation if and when it comes to market.

They either have P results and/or new controlling party wants P due to the results or to have control of future P decisions.
Ex. Celgene takes controlling stake- B-OM offsets investment, B-IBD adds incentive, Prurisol delayed to maintain Otezla’s blockbuster revenue until generic and Prurisol is ready for market and Kevetrin being the dark horse that could be explosive yet not counted on.